四川成渝(601107.SH):擬不超過22億元購買荊宜公司85%股權
格隆匯8月14日丨四川成渝(601107.SH)公佈,擬通過發行股份及支付現金方式,購買蜀道創投持有的荊宜公司85%的股權,截至本預案簽署日,標的公司的審計和評估工作尚未完成,標的資產評估值及交易作價均尚未確定,交易價格預計不超過人民幣22億元。
上市公司通過本次交易收購荊宜公司85%股權,有利於增加控股的高速公路項目,進一步提高上市公司資產規模、擴大利潤來源。與此同時,荊宜公司的注入能夠延長上市公司下屬路產運營里程,有效提升上市公司可持續發展能力,促進上市公司優化資產結構、鞏固核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.